Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under ...

CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...